- Home
- PMCB vs NCNA Comparison
PMCB vs NCNA Comparison
Compare PMCB & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PMCB | NCNA |
|---|---|---|
| Founded | 1996 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0M | 4.0M |
| IPO Year | 2001 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PMCB | NCNA |
|---|---|---|
| Price | $0.42 | $0.94 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 97.6K | 25.6K |
| Earning Date | 12-17-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.90 |
| 52 Week High | $1.51 | $4.55 |
Technical Indicators
Market Signals| Indicator | PMCB | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 33.17 |
| Support Level | $0.32 | N/A |
| Resistance Level | $0.77 | $1.40 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 91.64 | 0.00 |
Price Performance
Historical ComparisonAbout PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.